A New Contender Enters the Ring: Ascletis Gains Key FDA Nod for Oral Diabetes Drug Ascletis Pharma has secured a critical milestone in the competitive metabolic disease landscape, receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This approval
An administrative failure of unprecedented scale has placed tens of thousands of Malaysia's medical professionals in a state of legal limbo, threatening the continuity of nationwide healthcare services as the 2026 calendar year begins. An extensive backlog in the issuance of the Annual
For decades, the journey to bring a new drug to market has been a marathon of immense cost and crushing uncertainty, with countless promising therapies failing long before they could reach the patients who needed them. This grueling process, often stretching over a decade and consuming billions of
A landmark decision by the Drug Enforcement Administration and the Department of Health and Human Services to again extend telehealth prescribing flexibilities has successfully averted a significant disruption in care for millions of Americans. This pivotal policy trend, born from necessity during
The silent, intricate world of cellular pathology, once confined to the glass slide and the human eye, is now being decoded with unprecedented speed and precision by the powerful engines of artificial intelligence. Artificial Intelligence (AI) in digital pathology represents a significant
The torrent of personal health information generated every second from smartwatches, electronic records, and genetic tests is creating a multi-billion-dollar industry that currently operates in a dangerous and ill-defined legal gray area. This digital transformation, while promising a new era of
